cell-free DNA
Investigators Urge Additional Screening to Catch Maternal Cancer From Nonreportable NIPT Results
An NIH team detected maternal cancers in nearly half of individuals with unusual or nonreportable findings from cell-free DNA-based fetal aneuploidy tests.
Element Biosciences, Qiagen Targeted NGS Helps ID Urine-Based cfDNA Biomarkers in Breast Cancer
Premium
At the AMP annual meeting, a University Hospital Leipzig researcher described using the NGS workflow to find promising urine-based biomarkers in triple-negative breast cancer.
Grail Q3 Revenues Rise 39 Percent
Grail reported that strong sales of its blood-based Galleri cancer early detection test drove revenue growth in its first operating quarter as a public company.
Zymo Research Files Counterclaims Against Qiagen in Patent Lawsuit
In a lawsuit related to nucleic acid sample prep, Zymo accuses Qiagen of antitrust violations and improperly interfering with its contractual relations.
The research team looked at cell-free DNA fragmentation profiles across the genome combined with measurements of two key biomarkers to detect ovarian cancer.